Cell-free DNA analysis in current cancer clinical trials: a review.

Cisneros-Villanueva M, et al. Br J Cancer. 2022;126(3):391-400.

Projected reductions in absolute cancer–related deaths from diagnosing cancers before metastasis, 
2006–2015.

Clarke CA, et al. Cancer Epidemiol Biomarkers Prev. 2020;29(5):895-902.

Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?

Duffy MJ, et al. Clin Chem Lab Med. 2021;59(8):1353-1361.

Multi-cancer early detection: the new frontier in cancer early detection.

Guerra CE, et al. Annu Rev Med. 2024;75:67-81.

New genomic technologies for multi-cancer early detection: rethinking the scope of cancer screening.

Hackshaw A, et al. Cancer Cell. 2022;40(2):109-113.

Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA.

Liu MC, et al. Ann Oncol. 2020;31(6):745-759.

Multicancer screening: one size does not fit all.

Putcha G, et al. JCO Precis Oncol. 2021:574-576.

Modelled mortality benefits of multi-cancer early detection screening in England.

Sasieni P, et al. Br J Cancer. 2023;129(1):72-80.

Blood-based tests for multicancer early detection (PATHFINDER): a prospective cohort study.

Schrag D, et al. Lancet. 2023;402(10409):1251-1260.

Sensitivity, specificity, and predictive values: foundations, pliabilities, and pitfalls in research and practice.

Trevethan R. Front Public Health. 2017;5:307.

RELATED ACTIVITIES

Can You Compete in Early Cancer Detection?

Hot Topics in Blood-Based Cancer Screening

Key Information on Multi-Cancer Early Detection From 2023 Spring Oncology Meetings

Multi-Cancer Early Detection

Incorporating Blood-Based Screening Tools in Primary Care